Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis journalArticle 2016 Lueza, B.; Rotolo, F.; Bonastre, J.; Pignon, J. P.; Michiels, S.
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis journalArticle 2016 Ma, X.; Le Teuff, G.; Lacas, B.; Tsao, M. S.; Graziano, S.; Pignon, J. P.; Douillard, J. Y.; Le Chevalier, T.; Seymour, L.; Filipits, M.; Pirker, R.; Janne, P. A.; Shepherd, F. A.; Brambilla, E.; Soria, J. C.; Hainaut, P.; Group, L. A. C. E. Bio Collaborative
Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting journalArticle 2016 Martelli, N.; Hansen, P.; van den Brink, H.; Boudard, A.; Cordonnier, A. L.; Devaux, C.; Pineau, J.; Prognon, P.; Borget, I.
Advantages and disadvantages of 3-dimensional printing in surgery: A systematic review journalArticle 2016 Martelli, N.; Serrano, C.; van den Brink, H.; Pineau, J.; Prognon, P.; Borget, I.; El Batti, S.
New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues journalArticle 2016 Martelli, N.; van den Brink, H.; Borget, I.
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease journalArticle 2016 Marthey, L.; Mateus, C.; Mussini, C.; Nachury, M.; Nancey, S.; Grange, F.; Zallot, C.; Peyrin-Biroulet, L.; Rahier, J. F.; Bourdier de Beauregard, M.; Mortier, L.; Coutzac, C.; Soularue, E.; Lanoy, E.; Kapel, N.; Planchard, D.; Chaput, N.; Robert, C.; Carbonnel, F.
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study journalArticle 2016 Massard, C.; Oulhen, M.; Le Moulec, S.; Auger, N.; Foulon, S.; Abou-Lovergne, A.; Billiot, F.; Valent, A.; Marty, V.; Loriot, Y.; Fizazi, K.; Vielh, P.; Farace, F.
45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims? journalArticle 2016 Mazeron, R.; Petit, C.; Rivin, E.; Limkin, E.; Dumas, I.; Maroun, P.; Annede, P.; Martinetti, F.; Seisen, T.; Lefkopoulos, D.; Chargari, C.; Haie-Meder, C.
Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer journalArticle 2016 McKeever, M. R.; Sio, T. T.; Gunn, G. B.; Holliday, E. B.; Blanchard, P.; Kies, M. S.; Weber, R. S.; Frank, S. J.
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents journalArticle 2016 Merlevede, J.; Droin, N.; Qin, T.; Meldi, K.; Yoshida, K.; Morabito, M.; Chautard, E.; Auboeuf, D.; Fenaux, P.; Braun, T.; Itzykson, R.; de Botton, S.; Quesnel, B.; Commes, T.; Jourdan, E.; Vainchenker, W.; Bernard, O.; Pata-Merci, N.; Solier, S.; Gayevskiy, V.; Dinger, M. E.; Cowley, M. J.; Selimoglu-Buet, D.; Meyer, V.; Artiguenave, F.; Deleuze, J. F.; Preudhomme, C.; Stratton, M. R.; Alexandrov, L. B.; Padron, E.; Ogawa, S.; Koscielny, S.; Figueroa, M.; Solary, E.
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer journalArticle 2016 Michiels, S.; Pugliano, L.; Marguet, S.; Grun, D.; Barinoff, J.; Cameron, D.; Cobleigh, M.; Di Leo, A.; Johnston, S.; Gasparini, G.; Kaufman, B.; Marty, M.; Nekljudova, V.; Paluch-Shimon, S.; Penault-Llorca, F.; Slamon, D.; Vogel, C.; von Minckwitz, G.; Buyse, M.; Piccart, M.
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice journalArticle 2016 Michiels, S.; Ternes, N.; Rotolo, F.
Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells journalArticle 2016 Mittal, D.; Caramia, F.; Michiels, S.; Joensuu, H.; Kellokumpu-Lehtinen, P. L.; Sotiriou, C.; Loi, S.; Smyth, M. J.
Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? journalArticle 2016 Ou, D.; Levy, A.; Blanchard, P.; Nguyen, F.; Garberis, I.; Casiraghi, O.; Scoazec, J. Y.; Janot, F.; Temam, S.; Deutsch, E.; Tao, Y.
Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma journalArticle 2016 Peeler, C. R.; Mirkovic, D.; Titt, U.; Blanchard, P.; Gunther, J. R.; Mahajan, A.; Mohan, R.; Grosshans, D. R.
MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity journalArticle 2016 Petit, C.; Dumas, I.; Chargari, C.; Martinetti, F.; Maroun, P.; Doyeux, K.; Tailleur, A.; Haie-Meder, C.; Mazeron, R.
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial journalArticle 2016 Piperno-Neumann, S.; Le Deley, M. C.; Redini, F.; Pacquement, H.; Marec-Berard, P.; Petit, P.; Brisse, H.; Lervat, C.; Gentet, J. C.; Entz-Werle, N.; Italiano, A.; Corradini, N.; Bompas, E.; Penel, N.; Tabone, M. D.; Gomez-Brouchet, A.; Guinebretiere, J. M.; Mascard, E.; Gouin, F.; Chevance, A.; Bonnet, N.; Blay, J. Y.; Brugieres, L.; Sarcoma Group of, Unicancer; French Society of Pediatric, Oncology; French Sarcoma, Group
Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution journalArticle 2016 Proust-Houdemont, S.; Pasqualini, C.; Blanchard, P.; Dufour, C.; Benhamou, E.; Goma, G.; Semeraro, M.; Raquin, M. A.; Hartmann, O.; Valteau-Couanet, D.
[A new classification for meibomian gland diseases with in vivo confocal microscopy] journalArticle 2016 Randon, M.; Liang, H.; Abbas, R.; Michee, S.; Denoyer, A.; Baudouin, C.; Labbe, A.
Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma journalArticle 2016 Regairaz, M.; Munier, F.; Sartelet, H.; Castaing, M.; Marty, V.; Renauleaud, C.; Doux, C.; Delbe, J.; Courty, J.; Fabre, M.; Ohta, S.; Vielh, P.; Michiels, S.; Valteau-Couanet, D.; Vassal, G.
The 5000% case: a glimpse into the financial issue of lung cancer treatment journalArticle 2016 Remon, J.; Bonastre, J.; Besse, B.
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial journalArticle 2016 Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G.
Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients journalArticle 2016 Rodriguez, C.; Suciu, V.; Poterie, A.; Lacroix, L.; Miran, I.; Boichard, A.; Delaloge, S.; Deneuve, J.; Azoulay, S.; Mathieu, M. C.; Valent, A.; Michiels, S.; Arnedos, M.; Vielh, P.
Incorporation of nested frailties into semiparametric multi-state models journalArticle 2016 Rotolo, F.; Rondeau, V.; Legrand, C.
Modalités de surveillance des patients suivis pour un cancer de la prostate avancé : résultats d’une enquête nationale de pratique journalArticle 2016 Rozet, F.; Roupret, M.; Hennequin, C.; Massard, C.; Blanchard, P.; Le moulec, S.
Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries journalArticle 2016 Saghatchian, M.; Fadoukhair, Z.; Hofert, K.; Lanoy, E.; Mathieu, M. C.; Mazouni, C.; Delaloge, S.
Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data journalArticle 2016 Singhal, S. K.; Usmani, N.; Michiels, S.; Metzger-Filho, O.; Saini, K. S.; Kovalchuk, O.; Parliament, M.
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes journalArticle 2016 Sio, T. T.; Lin, H. K.; Shi, Q.; Gunn, G. B.; Cleeland, C. S.; Lee, J. J.; Hernandez, M.; Blanchard, P.; Thaker, N. G.; Phan, J.; Rosenthal, D. I.; Garden, A. S.; Morrison, W. H.; Fuller, C. D.; Mendoza, T. R.; Mohan, R.; Wang, X. S.; Frank, S. J.
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene journalArticle 2016 van Kempen, L. C.; Redpath, M.; Elchebly, M.; Klein, K. O.; Papadakis, A. I.; Wilmott, J. S.; Scolyer, R. A.; Edqvist, P. H.; Ponten, F.; Schadendorf, D.; van Rijk, A. F.; Michiels, S.; Dumay, A.; Helbling-Leclerc, A.; Dessen, P.; Wouters, J.; Stass, M.; Greenwood, C. M.; Ghanem, G. E.; van den Oord, J.; Feunteun, J.; Spatz, A.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy journalArticle 2017 Annede, P.; Seisen, T.; Klotz, C.; Mazeron, R.; Maroun, P.; Petit, C.; Deutsch, E.; Bossi, A.; Haie-Meder, C.; Chargari, C.; Blanchard, P.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents journalArticle 2017 Azan, A.; Caspers, P. J.; Bakker Schut, T. C.; Roy, S.; Boutros, C.; Mateus, C.; Routier, E.; Besse, B.; Planchard, D.; Seck, A.; Kamsu Kom, N.; Tomasic, G.; Koljenovic, S.; Noordhoek Hegt, V.; Texier, M.; Lanoy, E.; Eggermont, A. M.; Paci, A.; Robert, C.; Puppels, G. J.; Mir, L. M.
Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma journalArticle 2017 Bacorro, W.; Escande, A.; Temam, S.; Dumas, I.; Routier, E.; Gensse, M. C.; Blanchard, P.; Janot, F.; Mateus, C.; Tao, Y.; Robert, C.; Deutsch, E.; Haie-Meder, C.; Chargari, C.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
Statistical approaches for evaluating body composition markers in clinical cancer research journalArticle 2017 Bayar, M. A.; Antoun, S.; Lanoy, E.